# Pembrolizumab

Source: https://onco.cc/drugs/pembrolizumab/  
OnCo record `pembrolizumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.

## Summary

Approvals span melanoma, NSCLC, head and neck, Hodgkin, urothelial, MSI-H/dMMR tumours (first tumour-agnostic approval, 2017), gastric, oesophageal, cervical, HCC, RCC, endometrial, TNBC (KEYNOTE-355 metastatic CPS ≥10; KEYNOTE-522 neoadjuvant/adjuvant with 7-year OS benefit), TMB-high, and more. 2026 additions include platinum-resistant PD-L1+ ovarian cancer, adjuvant RCC with belzutifan, and combination labels with sacituzumab govitecan (ASCENT-04) and enfortumab vedotin. Subcutaneous Keytruda Qlex approved 2025. Backbone for neoantigen vaccines (intismeran).

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-04
- Brand: Keytruda / Keytruda Qlex (SC)
- Modality: Monoclonal antibody (anti-PD-1)
- Mechanism: Humanised IgG4 blocking PD-1; restores T-cell effector function.
- Approvals: US 2014: Melanoma (first of >40 indications); US 2017: MSI-H/dMMR solid tumours (tumour-agnostic); US 2020: Metastatic TNBC, PD-L1 CPS ≥10, with chemotherapy; US 2021: High-risk early TNBC, neoadjuvant + adjuvant (KEYNOTE-522); US 2023: Locally advanced unresectable or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (KEYNOTE-966); US 2026: Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC; EU 2021: Locally recurrent unresectable or metastatic TNBC, PD-L1 CPS 10 or more, with chemotherapy, no prior chemotherapy for metastatic disease (KEYNOTE-355); EU 2022: Locally advanced or early-stage TNBC at high risk of recurrence: neoadjuvant with chemotherapy, then adjuvant monotherapy (KEYNOTE-522); UK 2022: Untreated triple-negative locally recurrent unresectable or metastatic breast cancer with paclitaxel or nab-paclitaxel; NICE TA801 (29 June 2022) recommends it only for tumours with CPS 10 or more and immune-cell staining below 1 percent (the atezolizumab population is carved out), under a commercial arrangement; UK 2022: Neoadjuvant with chemotherapy then adjuvant alone for triple-negative early breast cancer at high risk of recurrence or locally advanced disease; NICE TA851 (14 December 2022) recommends within the marketing authorisation, routine commissioning with a commercial arrangement; UK 2023: Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer; England (NICE) 2021: Untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency; England (NICE) 2023: Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer; England (NICE) 2018: Untreated PD-L1-positive metastatic non-small-cell lung cancer with a tumour proportion score of 50 percent or more and no EGFR or ALK alteration; England (NICE) 2021: Untreated metastatic non-squamous non-small-cell lung cancer without an EGFR or ALK alteration, with pemetrexed and platinum chemotherapy; England (NICE) 2022: Untreated metastatic squamous non-small-cell lung cancer, with carboplatin and paclitaxel; England (NICE) 2017: Locally advanced or metastatic PD-L1-positive non-small-cell lung cancer after at least one chemotherapy; England (NICE) 2024: Resectable non-small-cell lung cancer at high risk of recurrence, neoadjuvant with platinum chemotherapy then adjuvant alone; England (NICE) 2025: Adjuvant treatment of non-small-cell lung cancer at high risk of recurrence after complete resection and platinum chemotherapy
- Dosing: IV infusion over 30 min (subcutaneous Keytruda Qlex available); 200 mg every 3 weeks or 400 mg every 6 weeks; paediatric 2 mg/kg (max 200 mg) every 3 weeks; up to 24 months in most metastatic settings

## Notes

- Triple-negative breast cancer: metastatic use requires 22C3 CPS 10 or more, about 27% of unselected early tumours and 38% of KEYNOTE-355 screening (Cortes 2022, Sigurjonsdottir 2023); early-stage use in KEYNOTE-522 needs no PD-L1 test.
- Triple-negative breast cancer, UK status: two NICE appraisals are in force (TA851 early disease, TA801 metastatic CPS 10 or more with immune-cell staining below 1 percent). A third, pembrolizumab as adjuvant treatment after neoadjuvant chemotherapy alone (GID-TA11724, the SWOG S1418 question), is awaiting development, and the appraisal of pembrolizumab for previously treated metastatic disease (GID-TA10295, KEYNOTE-119) was discontinued after that trial missed its primary endpoint.
- Pancreatic cancer: the Keytruda label's tumour-agnostic MSI-H or dMMR indication rests on KEYNOTE-158, whose pancreatic cohort had 4 responses in 22 patients (18 percent; 95 percent confidence interval 5 to 40; duration 8.1 to 24.3 or more months). In the EU the MSI-H indication names colorectal, endometrial, gastric, small intestine and biliary cancer and in England NICE TA914 mirrors that list, so mismatch repair deficient pancreatic cancer (about 1 percent of cases) has no funded checkpoint inhibitor route in Europe outside trials such as the Cambridge-led pembrolizumab and olaparib study (NCT05093231, 15 UK sites).
- Pancreatic ductal adenocarcinoma: the threshold is MSI-high or mismatch repair deficiency, about 1% of cases; KEYNOTE-158's pancreatic cohort gave 4 responses among 22 patients against 34.3% across all non-colorectal MSI-high tumours (Marabelle 2020). PD-L1 expression is not a threshold in this disease and unselected checkpoint blockade has failed.
- Colorectal cancer biomarkers: MSI-high or mismatch repair deficiency, about 5% of metastatic and 10 to 15% of resected disease. The first study gave 4 responses in 10 deficient colorectal cancers and 0 in 18 proficient ones (Le 2015). PD-L1 expression and tumour mutational burden are not colorectal thresholds; universal mismatch repair testing identifies the eligible patients as a by-product of Lynch syndrome screening (Moreira 2012).

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Pembrolizumab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pembrolizumab
- NICE TA851: pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (14 December 2022): https://www.nice.org.uk/guidance/ta851
- NICE TA801: pembrolizumab plus chemotherapy for untreated triple-negative metastatic breast cancer (29 June 2022): https://www.nice.org.uk/guidance/ta801
- Keytruda label (openFDA): TNBC indications and KEYNOTE-522, KEYNOTE-355 and KEYNOTE-D19 study sections: https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22KEYTRUDA%22
- NICE TA914 (20 September 2023): https://www.nice.org.uk/guidance/ta914
- NICE TA709: pembrolizumab for untreated MSI-high or dMMR metastatic colorectal cancer: https://www.nice.org.uk/guidance/ta709
- NICE TA531: pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta531
- NICE TA683: pembrolizumab with pemetrexed and platinum chemotherapy for untreated metastatic non-squamous non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta683
- NICE TA770: pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta770
- NICE TA1017: pembrolizumab neoadjuvant then adjuvant for resectable non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta1017
- NICE TA1037: pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer: https://www.nice.org.uk/guidance/ta1037

## Connected records

- technologies: [Cannabis and cannabinoids for pain, appetite and cancer control](https://onco.cc/technologies/cannabinoids-pain-appetite/), [Dietary fibre and the gut microbiome for immunotherapy response](https://onco.cc/technologies/dietary-fibre-microbiome-io/), [Downstream purification (Protein A capture, viral clearance, polishing)](https://onco.cc/technologies/downstream-purification-chromatography/), [Faecal microbiota transplantation for PD-1 non-responders](https://onco.cc/technologies/fmt-checkpoint-nonresponders/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Immune endocrine damage is usually permanent, and almost nobody is told](https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/), [MSI and mismatch-repair testing](https://onco.cc/technologies/msi-mmr-testing/), [Probiotics, antibiotics and stewardship around immunotherapy](https://onco.cc/technologies/probiotics-antibiotic-stewardship-io/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/), [Tumour mutational burden testing](https://onco.cc/technologies/tmb-testing/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/)
- biomarkers: [9p24.1 alteration of the PD-1 ligand loci](https://onco.cc/biomarkers/pd-ligand-9p24-alteration/), [dMMR (mismatch repair deficiency by IHC)](https://onco.cc/biomarkers/dmmr-ihc/), [MSI-high (microsatellite instability by PCR or sequencing)](https://onco.cc/biomarkers/msi-high/), [PD-L1 CPS (combined positive score)](https://onco.cc/biomarkers/pd-l1-cps/), [PD-L1 TPS (tumour proportion score)](https://onco.cc/biomarkers/pd-l1-tps/), [TMB-high (tumour mutational burden >= 10 mutations per megabase)](https://onco.cc/biomarkers/tmb-high/)
- cancers: [Acral melanoma](https://onco.cc/cancers/acral-melanoma/), [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/), [Adenosquamous carcinoma of the cervix](https://onco.cc/cancers/cervical-adenosquamous-carcinoma/), [Adrenocortical carcinoma](https://onco.cc/cancers/adrenocortical/), [Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)](https://onco.cc/cancers/advanced-adrenocortical-carcinoma/), [Advanced and metastatic small bowel adenocarcinoma](https://onco.cc/cancers/advanced-small-bowel-adenocarcinoma/), [Advanced cutaneous squamous cell carcinoma](https://onco.cc/cancers/advanced-cutaneous-scc/), [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Advanced or recurrent endometrial cancer](https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/), [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Ampullary cancer (ampulla of Vater)](https://onco.cc/cancers/ampullary/), [Anal cancer (squamous cell carcinoma)](https://onco.cc/cancers/anal/), [Anaplastic thyroid cancer](https://onco.cc/cancers/anaplastic-thyroid-cancer/), [Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)](https://onco.cc/cancers/appendiceal-adenocarcinoma/), [Basal-like 1 triple-negative breast cancer (BL1)](https://onco.cc/cancers/tnbc-basal-like-1/), [Basal-like 2 triple-negative breast cancer (BL2)](https://onco.cc/cancers/tnbc-basal-like-2/), [Basaloid squamous cell carcinoma of the lung](https://onco.cc/cancers/basaloid-squamous-cell-carcinoma-lung/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/), [Buccal mucosa and gingivobuccal cancer (oral cancer in India)](https://onco.cc/cancers/buccal-mucosa-cancer/), [Cancer of unknown primary (CUP)](https://onco.cc/cancers/cancer-of-unknown-primary/), [Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)](https://onco.cc/cancers/cup-unfavourable/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Claudin 18.2-positive gastric cancer](https://onco.cc/cancers/gastric-cldn18-2-positive/), [Clear cell ovarian cancer](https://onco.cc/cancers/clear-cell-ovarian-cancer/), [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Conjunctival melanoma](https://onco.cc/cancers/conjunctival-melanoma/), [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Cystic duct carcinoma](https://onco.cc/cancers/cystic-duct-carcinoma/), [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Early-onset colorectal cancer (under 50)](https://onco.cc/cancers/early-onset-colorectal/), [Early-stage classical Hodgkin lymphoma (stage I to II)](https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Endometrial cancer with no specific molecular profile](https://onco.cc/cancers/endometrial-nsmp/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Extranodal NK/T-cell lymphoma](https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/), [Gallbladder adenocarcinoma](https://onco.cc/cancers/gallbladder-adenocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Gestational trophoblastic neoplasia](https://onco.cc/cancers/gestational-trophoblastic/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)](https://onco.cc/cancers/high-risk-gtn/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [HPV-associated vulvar squamous cell carcinoma](https://onco.cc/cancers/hpv-associated-vulvar-cancer/), [HPV-independent vulvar squamous cell carcinoma (p53-mutant)](https://onco.cc/cancers/hpv-independent-vulvar-cancer/), [HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)](https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/), [HPV-positive oropharyngeal cancer](https://onco.cc/cancers/hpv-positive-oropharyngeal-cancer/), [Hypopharyngeal cancer](https://onco.cc/cancers/hypopharyngeal-cancer/), [Immunomodulatory triple-negative breast cancer (IM)](https://onco.cc/cancers/tnbc-immunomodulatory/), [Incidental gallbladder cancer (found after cholecystectomy)](https://onco.cc/cancers/incidental-gallbladder-cancer/), [Inflammatory breast cancer](https://onco.cc/cancers/inflammatory-breast-cancer/), [Intermediate hepatocellular carcinoma (BCLC B)](https://onco.cc/cancers/hcc-intermediate/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/), [Kaposi sarcoma](https://onco.cc/cancers/kaposi-sarcoma/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Large cell carcinoma of the lung](https://onco.cc/cancers/large-cell-lung-carcinoma/), [Laryngeal and hypopharyngeal cancer](https://onco.cc/cancers/laryngeal-cancer/), [Lip cancer](https://onco.cc/cancers/lip-cancer/), [Locally advanced cervical cancer](https://onco.cc/cancers/locally-advanced-cervical-cancer/), [Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)](https://onco.cc/cancers/low-risk-gtn/), [Luminal androgen receptor triple-negative breast cancer (LAR)](https://onco.cc/cancers/tnbc-luminal-androgen-receptor/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Lymphoepithelial carcinoma of the lung](https://onco.cc/cancers/lymphoepithelial-carcinoma-lung/), [Medullary carcinoma of the colon](https://onco.cc/cancers/colorectal-medullary-carcinoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Melanoma of the urethra](https://onco.cc/cancers/urethral-melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Mesenchymal stem-like triple-negative breast cancer (MSL)](https://onco.cc/cancers/tnbc-mesenchymal-stem-like/), [Mesenchymal triple-negative breast cancer (M)](https://onco.cc/cancers/tnbc-mesenchymal/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Metaplastic breast carcinoma](https://onco.cc/cancers/metaplastic-breast-carcinoma/), [Metastatic and recurrent anal squamous cell carcinoma](https://onco.cc/cancers/metastatic-anal-cancer/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Microsatellite-unstable (MSI-high) gastric cancer](https://onco.cc/cancers/gastric-msi-high/), [Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma](https://onco.cc/cancers/msi-high-pdac/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Mismatch-repair-deficient endometrial cancer](https://onco.cc/cancers/endometrial-mmr-deficient/), [Mucinous adenocarcinoma of the colon and rectum](https://onco.cc/cancers/colorectal-mucinous-adenocarcinoma/), [Mucoepidermoid carcinoma](https://onco.cc/cancers/mucoepidermoid-carcinoma/), [Mucosal melanoma](https://onco.cc/cancers/mucosal-melanoma/), [Muscle-invasive and advanced bladder cancer](https://onco.cc/cancers/muscle-invasive-bladder-cancer/), [Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)](https://onco.cc/cancers/sinonasal/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Neuroendocrine and small-cell prostate cancer](https://onco.cc/cancers/prostate-nepc/), [Node-positive and metastatic penile cancer](https://onco.cc/cancers/node-positive-penile-cancer/), [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [NTRK fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ntrk-fusion-nsclc/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/), [Oral cavity cancer (mouth and tongue)](https://onco.cc/cancers/oral-cavity-cancer/), [Oral tongue and floor of mouth cancer](https://onco.cc/cancers/oral-tongue-cancer/), [Oropharyngeal cancer (tonsil and base of tongue)](https://onco.cc/cancers/oropharyngeal-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [p53-abnormal endometrial cancer, including uterine serous carcinoma](https://onco.cc/cancers/endometrial-p53-abnormal/), [Paediatric high-grade glioma (excluding diffuse midline glioma)](https://onco.cc/cancers/paediatric-high-grade-glioma/), [Pancreatic acinar cell carcinoma](https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Papillary renal cell carcinoma](https://onco.cc/cancers/papillary-rcc/), [PD-L1-high gastric cancer](https://onco.cc/cancers/gastric-pdl1-high/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Penile cancer](https://onco.cc/cancers/penile/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Peritoneal mesothelioma](https://onco.cc/cancers/peritoneal-mesothelioma/), [Placental-site trophoblastic tumour and epithelioid trophoblastic tumour](https://onco.cc/cancers/placental-site-trophoblastic-tumour/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/), [Pleural mesothelioma](https://onco.cc/cancers/pleural-mesothelioma/), [POLE-ultramutated endometrial cancer](https://onco.cc/cancers/endometrial-pole-ultramutated/), [Primary mediastinal (thymic) large B-cell lymphoma](https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Recurrent and metastatic nasopharyngeal carcinoma](https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/), [Recurrent or metastatic cervical cancer](https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/), [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/), [Relapsed and refractory classical Hodgkin lymphoma](https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [RET fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ret-fusion-nsclc/), [Salivary duct carcinoma](https://onco.cc/cancers/salivary-duct-carcinoma/), [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma](https://onco.cc/cancers/sinonasal-undifferentiated-carcinoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Small intestine cancer (small bowel adenocarcinoma)](https://onco.cc/cancers/small-bowel/), [Soft tissue sarcoma of the extremity (localised and advanced)](https://onco.cc/cancers/extremity-soft-tissue-sarcoma/), [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/), [Stage IIB and IIC melanoma](https://onco.cc/cancers/stage-ii-melanoma/), [Stage III melanoma (after surgery)](https://onco.cc/cancers/stage-iii-melanoma/), [Thymic carcinoma](https://onco.cc/cancers/thymic-carcinoma/), [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/), [Thyroid cancer](https://onco.cc/cancers/thyroid/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Undifferentiated pleomorphic sarcoma (UPS)](https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/), [Urethral cancer](https://onco.cc/cancers/urethral/), [Urothelial carcinoma of the urethra](https://onco.cc/cancers/urethral-urothelial-carcinoma/), [Uterine carcinosarcoma](https://onco.cc/cancers/uterine-carcinosarcoma/), [Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)](https://onco.cc/cancers/vaginal-adenocarcinoma/), [Vaginal cancer](https://onco.cc/cancers/vaginal/), [Vaginal melanoma](https://onco.cc/cancers/vaginal-melanoma/), [Vaginal squamous cell carcinoma (HPV-associated)](https://onco.cc/cancers/vaginal-squamous-cell-carcinoma/), [Vulvar cancer](https://onco.cc/cancers/vulvar/), [Vulvar melanoma](https://onco.cc/cancers/vulvar-melanoma/)
- targets: [LILRB1 (ILT2)](https://onco.cc/targets/lilrb1/), [LILRB2 (ILT4)](https://onco.cc/targets/lilrb2/), [Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)](https://onco.cc/targets/mmr/), [OX40 (TNFRSF4)](https://onco.cc/targets/tnfrsf4/), [PD-1](https://onco.cc/targets/pd1/)
- companies: [Alliance for Clinical Trials in Oncology](https://onco.cc/companies/alliance-oncology/), [BioLineRx](https://onco.cc/companies/biolinerx/), [GI Innovation](https://onco.cc/companies/gi-innovation/), [GOG Foundation](https://onco.cc/companies/gog-foundation/), [GV20 Therapeutics](https://onco.cc/companies/gv20-therapeutics/), [Immunovaccine (IMV)](https://onco.cc/companies/immunovaccine/), [Immutep](https://onco.cc/companies/immutep/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Precigen](https://onco.cc/companies/precigen/), [Qurient](https://onco.cc/companies/qurient/), [Salubris Biotherapeutics](https://onco.cc/companies/salubris-biotherapeutics/), [Teclison](https://onco.cc/companies/teclison/)
- trials: [A Beta-only IL-2 ImmunoTherapY Study](https://onco.cc/trials/nct05086692/), [A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)](https://onco.cc/trials/nct06961006/), [A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)](https://onco.cc/trials/nct06305767/), [A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva](https://onco.cc/trials/nct04370587/), [A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)](https://onco.cc/trials/nct06428409/), [A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)](https://onco.cc/trials/nct06698042/), [A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)](https://onco.cc/trials/nct06843447/), [A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc](https://onco.cc/trials/nct07216703/), [A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)](https://onco.cc/trials/nct06966700/), [A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma](https://onco.cc/trials/nct04657991/), [A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC](https://onco.cc/trials/nct07255664/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06868277/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N](https://onco.cc/trials/nct06627647/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s](https://onco.cc/trials/nct06692738/), [A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung](https://onco.cc/trials/nct05984277/), [A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F](https://onco.cc/trials/nct07591597/), [A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct07632235/), [A Phase 1/2 Study of BA3071 in Patients With Solid Tumors](https://onco.cc/trials/nct05180799/), [A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors](https://onco.cc/trials/nct07020221/), [A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05585320/), [A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC](https://onco.cc/trials/nct06246110/), [A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849](https://onco.cc/trials/nct05761223/), [A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P](https://onco.cc/trials/nct07743190/), [A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab](https://onco.cc/trials/nct07318883/), [A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07269158/), [A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer](https://onco.cc/trials/nct06112379/), [A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer](https://onco.cc/trials/nct06764875/), [A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer](https://onco.cc/trials/nct05565378/), [A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca](https://onco.cc/trials/nct07054242/), [A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma](https://onco.cc/trials/nct05309421/), [A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance](https://onco.cc/trials/nct06822543/), [A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies](https://onco.cc/trials/nct07415031/), [A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs](https://onco.cc/trials/nct06228326/), [A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05970497/), [A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC](https://onco.cc/trials/nct07807163/), [A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi](https://onco.cc/trials/nct05920356/), [A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip](https://onco.cc/trials/nct06793215/), [A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par](https://onco.cc/trials/nct05789082/), [A Study in Patients With Advanced Cancers](https://onco.cc/trials/nct05320588/), [A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)](https://onco.cc/trials/nct06875310/), [A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).](https://onco.cc/trials/nct06307431/), [A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer](https://onco.cc/trials/nct06385080/), [A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer](https://onco.cc/trials/nct07276399/), [A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors](https://onco.cc/trials/nct03611868/), [A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ](https://onco.cc/trials/nct06699212/), [A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors](https://onco.cc/trials/nct07287995/), [A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors](https://onco.cc/trials/nct07730021/), [A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06472076/), [A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct03526835/), [A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer](https://onco.cc/trials/nct07054567/), [A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06978114/), [A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer](https://onco.cc/trials/nct06962787/), [A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS](https://onco.cc/trials/nct07264816/), [A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC](https://onco.cc/trials/nct07178795/), [A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation](https://onco.cc/trials/nct05410145/), [A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2](https://onco.cc/trials/nct04879329/), [A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.](https://onco.cc/trials/nct07315750/), [A Study of DS-3939a in Participants With Solid Tumors](https://onco.cc/trials/nct07739966/), [A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)](https://onco.cc/trials/nct05845814/), [A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)](https://onco.cc/trials/nct06483334/), [A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic](https://onco.cc/trials/nct05217446/), [A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer](https://onco.cc/trials/nct06119581/), [A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies](https://onco.cc/trials/nct05669430/), [A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel](https://onco.cc/trials/nct05805501/), [A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (](https://onco.cc/trials/nct06077760/), [A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)](https://onco.cc/trials/nct07221474/), [A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma](https://onco.cc/trials/nct07815665/), [A Study of NDI 1150-101 in Patients With Solid Tumors](https://onco.cc/trials/nct05128487/), [A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol](https://onco.cc/trials/nct06099782/), [A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)](https://onco.cc/trials/nct06041802/), [A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study](https://onco.cc/trials/nct05899049/), [A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)](https://onco.cc/trials/nct02332668/), [A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)](https://onco.cc/trials/nct06623422/), [A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)](https://onco.cc/trials/nct07302347/), [A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34](https://onco.cc/trials/nct06731907/), [A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat](https://onco.cc/trials/nct04683679/), [A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)](https://onco.cc/trials/nct06312176/), [A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)](https://onco.cc/trials/nct06841354/), [A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-](https://onco.cc/trials/nct05816252/), [A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P](https://onco.cc/trials/nct06711900/), [A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06448312/), [A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07622186/), [A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)](https://onco.cc/trials/nct05722015/), [A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension](https://onco.cc/trials/nct06212752/), [A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07672223/), [A Study of Tetrathiomolybdate (TM) Plus Capecitabine](https://onco.cc/trials/nct06134375/), [A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer](https://onco.cc/trials/nct05852691/), [A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer](https://onco.cc/trials/nct07679360/), [A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma](https://onco.cc/trials/nct05440708/), [A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct06644768/), [A Study of YL242 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct07197827/), [A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer](https://onco.cc/trials/nct03505320/), [A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer](https://onco.cc/trials/nct06901531/), [A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm](https://onco.cc/trials/nct06312137/), [A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan](https://onco.cc/trials/nct07756645/), [A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06311721/), [A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer](https://onco.cc/trials/nct06939595/), [A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan](https://onco.cc/trials/nct06952504/), [A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N](https://onco.cc/trials/nct06561386/), [A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s](https://onco.cc/trials/nct06348199/), [A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct07749586/), [A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)](https://onco.cc/trials/nct04225117/), [A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)](https://onco.cc/trials/nct05319730/), [A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme](https://onco.cc/trials/nct05053880/), [A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer](https://onco.cc/trials/nct05318573/), [A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese](https://onco.cc/trials/nct07541170/), [A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat](https://onco.cc/trials/nct06797297/), [A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P](https://onco.cc/trials/nct07361510/), [A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum](https://onco.cc/trials/nct07811193/), [A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.](https://onco.cc/trials/nct06116136/), [A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu](https://onco.cc/trials/nct05824975/), [A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance](https://onco.cc/trials/nct07223047/), [A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06618287/), [A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder](https://onco.cc/trials/nct07475806/), [A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)](https://onco.cc/trials/nct07286266/), [A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other](https://onco.cc/trials/nct05081609/), [A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N](https://onco.cc/trials/nct05048797/), [A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS](https://onco.cc/trials/nct06008093/), [A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma](https://onco.cc/trials/nct06452277/), [A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)](https://onco.cc/trials/nct05562830/), [A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer](https://onco.cc/trials/nct06545955/), [A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af](https://onco.cc/trials/nct05608291/), [ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07158918/), [Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden](https://onco.cc/trials/nct07715396/), [ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05405595/), [Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm](https://onco.cc/trials/nct04317534/), [ALEXANDRA / IMpassion030](https://onco.cc/trials/impassion030/), [An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN](https://onco.cc/trials/nct03897881/), [An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC](https://onco.cc/trials/nct07720284/), [An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors](https://onco.cc/trials/nct04305795/), [ASCENT-04 / KEYNOTE-D19](https://onco.cc/trials/ascent-04/), [ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)](https://onco.cc/trials/ascent-05/), [ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation](https://onco.cc/trials/nct07015853/), [AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.](https://onco.cc/trials/nct06137144/), [BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07469774/), [Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab](https://onco.cc/trials/nct07486817/), [Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment](https://onco.cc/trials/nct06151574/), [Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati](https://onco.cc/trials/nct07195695/), [BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)](https://onco.cc/trials/nct04752826/), [BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06205706/), [Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer](https://onco.cc/trials/nct06530303/), [Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial](https://onco.cc/trials/nct07610525/), [Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets](https://onco.cc/trials/nct05317858/), [c-TRAK TN](https://onco.cc/trials/c-trak-tn/), [Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery](https://onco.cc/trials/nct05973864/), [Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial](https://onco.cc/trials/nct06096844/), [CLEAR (KEYNOTE-581)](https://onco.cc/trials/clear/), [Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1](https://onco.cc/trials/nct06767514/), [Clinical Trial of TB511 in Advanced Solid Tumors](https://onco.cc/trials/nct06400160/), [Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06293651/), [CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen](https://onco.cc/trials/nct06699836/), [Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Incl](https://onco.cc/trials/nct07762703/), [Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation](https://onco.cc/trials/nct05609578/), [Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer](https://onco.cc/trials/nct05909423/), [Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct06632327/), [Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)](https://onco.cc/trials/nct06502080/), [Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma](https://onco.cc/trials/nct04339218/), [Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)](https://onco.cc/trials/nct05555732/), [DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC](https://onco.cc/trials/nct06989112/), [Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma](https://onco.cc/trials/nct06784648/), [Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07159217/), [Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2](https://onco.cc/trials/nct05911295/), [DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp](https://onco.cc/trials/nct04920617/), [EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer](https://onco.cc/trials/ea2197-ivonescimab/), [EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors](https://onco.cc/trials/nct07410676/), [EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma](https://onco.cc/trials/nct06556563/), [Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors](https://onco.cc/trials/nct05055908/), [Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients](https://onco.cc/trials/nct06028633/), [Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)](https://onco.cc/trials/nct03711032/), [Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)](https://onco.cc/trials/nct04241185/), [Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors](https://onco.cc/trials/nct03485209/), [EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic](https://onco.cc/trials/nct07262619/), [ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors](https://onco.cc/trials/nct04205227/), [Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)](https://onco.cc/trials/nct07566156/), [EORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer](https://onco.cc/trials/eortc-1607-pembro-cisgem/), [EV-302 / KEYNOTE-A39](https://onco.cc/trials/ev-302/), [EV-303 / KEYNOTE-905](https://onco.cc/trials/ev-303/), [EV-304 / KEYNOTE-B15](https://onco.cc/trials/ev-304/), [Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors](https://onco.cc/trials/nct07095868/), [Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ](https://onco.cc/trials/nct04895722/), [Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)](https://onco.cc/trials/nct04675333/), [Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)](https://onco.cc/trials/nct04675294/), [Fianlimab + cemiplimab phase 3 (first-line melanoma)](https://onco.cc/trials/fianlimab-phase3-melanoma/), [First in Human Study of T3P-Y058-739 (T3P)](https://onco.cc/trials/nct05120596/), [First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors](https://onco.cc/trials/nct06877650/), [First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05438329/), [FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)](https://onco.cc/trials/fmt-pd1-refractory-melanoma-pitt/), [FORTIFI-HN01](https://onco.cc/trials/fortifi-hn01/), [Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma](https://onco.cc/trials/nct06484153/), [Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07710885/), [GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites](https://onco.cc/trials/nct05438459/), [GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors](https://onco.cc/trials/nct04083599/), [GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors](https://onco.cc/trials/nct04977453/), [Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients](https://onco.cc/trials/nct04121455/), [GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors](https://onco.cc/trials/nct06265025/), [GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab](https://onco.cc/trials/nct04652076/), [HARMONi-2](https://onco.cc/trials/harmoni-2/), [HARMONi-3](https://onco.cc/trials/harmoni-3/), [High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct06492759/), [Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors](https://onco.cc/trials/nct05394103/), [I-SPY 2](https://onco.cc/trials/i-spy-2/), [I-SPY 2.2](https://onco.cc/trials/i-spy-2-2/), [IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small](https://onco.cc/trials/nct07122687/), [IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma](https://onco.cc/trials/nct05987332/), [ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07452224/), [Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer](https://onco.cc/trials/nct01174121/), [IMpassion131](https://onco.cc/trials/impassion131/), [IND.227 / KEYNOTE-483](https://onco.cc/trials/keynote-483/), [INTerpath-001 (V940-001)](https://onco.cc/trials/interpath-001/), [Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma](https://onco.cc/trials/nct06898970/), [Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)](https://onco.cc/trials/nct06634875/), [Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)](https://onco.cc/trials/nct05318469/), [Ixovex-1 Single Agent and Combination Therapy](https://onco.cc/trials/nct06549946/), [KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)](https://onco.cc/trials/nct04165070/), [KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)](https://onco.cc/trials/nct07252739/), [KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)](https://onco.cc/trials/nct07232602/), [KEYNOTE-006](https://onco.cc/trials/keynote-006/), [KEYNOTE-010](https://onco.cc/trials/keynote-010/), [KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)](https://onco.cc/trials/keynote-017/), [KEYNOTE-024 & KEYNOTE-189](https://onco.cc/trials/keynote-024-189/), [KEYNOTE-042](https://onco.cc/trials/keynote-042/), [KEYNOTE-048](https://onco.cc/trials/keynote-048/), [KEYNOTE-057](https://onco.cc/trials/keynote-057/), [KEYNOTE-062](https://onco.cc/trials/keynote-062/), [KEYNOTE-091 (PEARLS)](https://onco.cc/trials/keynote-091/), [KEYNOTE-119](https://onco.cc/trials/keynote-119/), [KEYNOTE-158](https://onco.cc/trials/keynote-158/), [KEYNOTE-170](https://onco.cc/trials/keynote-170/), [KEYNOTE-177](https://onco.cc/trials/keynote-177/), [KEYNOTE-204](https://onco.cc/trials/keynote-204/), [KEYNOTE-355](https://onco.cc/trials/keynote-355/), [KEYNOTE-407](https://onco.cc/trials/keynote-407/), [KEYNOTE-412](https://onco.cc/trials/keynote-412/), [KEYNOTE-426](https://onco.cc/trials/keynote-426/), [KEYNOTE-522](https://onco.cc/trials/keynote-522/), [KEYNOTE-564](https://onco.cc/trials/keynote-564/), [KEYNOTE-590](https://onco.cc/trials/keynote-590/), [KEYNOTE-629](https://onco.cc/trials/keynote-629/), [KEYNOTE-641](https://onco.cc/trials/keynote-641/), [KEYNOTE-671](https://onco.cc/trials/keynote-671/), [KEYNOTE-689](https://onco.cc/trials/keynote-689/), [KEYNOTE-716](https://onco.cc/trials/keynote-716/), [KEYNOTE-775 / Study 309](https://onco.cc/trials/keynote-775/), [KEYNOTE-811](https://onco.cc/trials/keynote-811/), [KEYNOTE-826](https://onco.cc/trials/keynote-826/), [KEYNOTE-859](https://onco.cc/trials/keynote-859/), [KEYNOTE-921](https://onco.cc/trials/keynote-921/), [KEYNOTE-966](https://onco.cc/trials/keynote-966/), [KEYNOTE-991](https://onco.cc/trials/keynote-991/), [KEYNOTE-A18 / ENGOT-cx11 / GOG-3047](https://onco.cc/trials/keynote-a18/), [KEYNOTE-B96 / ENGOT-ov65](https://onco.cc/trials/keynote-b96/), [LEAP-002](https://onco.cc/trials/leap-002/), [LEAP-012](https://onco.cc/trials/leap-012/), [Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)](https://onco.cc/trials/nct04592653/), [LiGeR-HN1](https://onco.cc/trials/liger-hn1/), [LITESPARK-012](https://onco.cc/trials/litespark-012/), [LITESPARK-022](https://onco.cc/trials/litespark-022/), [LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC](https://onco.cc/trials/nct06216301/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [Lung-MAP S1800A: ramucirumab plus pembrolizumab](https://onco.cc/trials/lung-map-s1800a/), [MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma](https://onco.cc/trials/mimic-01/), [MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer](https://onco.cc/trials/nct05462236/), [Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer](https://onco.cc/trials/nct05329532/), [Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors](https://onco.cc/trials/nct06493552/), [Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer](https://onco.cc/trials/nct05462496/), [N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors](https://onco.cc/trials/nct07639450/), [Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer](https://onco.cc/trials/nct04109755/), [NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)](https://onco.cc/trials/nct06081244/), [Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct06846268/), [Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC](https://onco.cc/trials/nct07016399/), [Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer](https://onco.cc/trials/nct05132504/), [Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients](https://onco.cc/trials/nct06353997/), [Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer](https://onco.cc/trials/nct07808151/), [Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer](https://onco.cc/trials/nct06407310/), [Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)](https://onco.cc/trials/nct06384560/), [Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer](https://onco.cc/trials/nct07188246/), [NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients](https://onco.cc/trials/nct06845319/), [NeoPACT](https://onco.cc/trials/neopact/), [NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC](https://onco.cc/trials/nct04335669/), [Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors](https://onco.cc/trials/nct04041310/), [Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer](https://onco.cc/trials/nct05485766/), [NRG-GY018 / KEYNOTE-868](https://onco.cc/trials/nrg-gy018-keynote-868/), [Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer](https://onco.cc/trials/nct04901741/), [ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer](https://onco.cc/trials/nct05446298/), [Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ](https://onco.cc/trials/nct05271318/), [Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T](https://onco.cc/trials/nct06318897/), [OptimICE-pCR (A012103)](https://onco.cc/trials/optimice-pcr/), [OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial](https://onco.cc/trials/nct06558214/), [Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors](https://onco.cc/trials/nct05438420/), [Patient Preference for Subcutaneous vs. Intravenous Immune Therapy](https://onco.cc/trials/nct07223424/), [PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct03774732/), [Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)](https://onco.cc/trials/nct03260894/), [Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)](https://onco.cc/trials/nct06788912/), [Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer](https://onco.cc/trials/nct06976944/), [Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC](https://onco.cc/trials/nct04153734/), [Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy](https://onco.cc/trials/nct07486687/), [Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)](https://onco.cc/trials/nct05623319/), [Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge](https://onco.cc/trials/nct05903833/), [Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)](https://onco.cc/trials/nct03358472/), [Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)](https://onco.cc/trials/nct04976634/), [PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %](https://onco.cc/trials/nct04547504/), [Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study](https://onco.cc/trials/nct04014530/), [Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer](https://onco.cc/trials/nct05093231/), [Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)](https://onco.cc/trials/nci-anetumab-pembrolizumab-mpm/), [Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06230471/), [Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287](https://onco.cc/trials/nct06422143/), [Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma](https://onco.cc/trials/nct02263508/), [Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)](https://onco.cc/trials/nct05224141/), [Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers](https://onco.cc/trials/nct06001658/), [Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct05269381/), [Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer](https://onco.cc/trials/nct06606730/), [PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC](https://onco.cc/trials/nct06245889/), [Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors](https://onco.cc/trials/nct03647163/), [Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)](https://onco.cc/trials/nct06430866/), [Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07162883/), [Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab](https://onco.cc/trials/nct06249048/), [Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab](https://onco.cc/trials/nct07751042/), [Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1](https://onco.cc/trials/nct03785249/), [Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors](https://onco.cc/trials/nct06795412/), [Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067](https://onco.cc/trials/nct04787042/), [Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors](https://onco.cc/trials/nct05945823/), [Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G](https://onco.cc/trials/nct04613596/), [Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors](https://onco.cc/trials/nct05797168/), [Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06708858/), [Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct05687266/), [Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥](https://onco.cc/trials/nct06357533/), [Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car](https://onco.cc/trials/nct06947928/), [Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-](https://onco.cc/trials/nct04624204/), [PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer](https://onco.cc/trials/nct06157151/), [Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer](https://onco.cc/trials/nct05741164/), [Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC](https://onco.cc/trials/nct06745882/), [QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors](https://onco.cc/trials/nct03228667/), [RAPA-201 Therapy of Solid Tumors](https://onco.cc/trials/nct05144698/), [Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation](https://onco.cc/trials/nct05491226/), [S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05101070/), [Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC](https://onco.cc/trials/nct04468061/), [Sacituzumab Govitecan In TNBC](https://onco.cc/trials/nct04230109/), [Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P](https://onco.cc/trials/nct06170788/), [Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)](https://onco.cc/trials/nct06393374/), [Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors](https://onco.cc/trials/nct04262466/), [Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis](https://onco.cc/trials/nct06047379/), [Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)](https://onco.cc/trials/nct03407144/), [Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct06016920/), [Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies](https://onco.cc/trials/nct04521413/), [Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer](https://onco.cc/trials/nct05117242/), [Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)](https://onco.cc/trials/nct04938817/), [Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors](https://onco.cc/trials/nct05732831/), [Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer](https://onco.cc/trials/nct06712316/), [Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC](https://onco.cc/trials/nct03970746/), [Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC](https://onco.cc/trials/nct04140526/), [Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer](https://onco.cc/trials/nct05877430/), [SARC028](https://onco.cc/trials/sarc028/), [SCARLET (SWOG S2212)](https://onco.cc/trials/scarlet-s2212/), [SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors](https://onco.cc/trials/nct05642780/), [Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct](https://onco.cc/trials/nct05482893/), [Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer](https://onco.cc/trials/nct05501665/), [STAMP (EA6174)](https://onco.cc/trials/stamp-merkel/), [Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab](https://onco.cc/trials/nct04130516/), [Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies](https://onco.cc/trials/nct04561362/), [Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)](https://onco.cc/trials/nct06225596/), [Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer](https://onco.cc/trials/nct04736173/), [Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors](https://onco.cc/trials/nct07287917/), [Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur](https://onco.cc/trials/nct03836352/), [Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer](https://onco.cc/trials/nct04093167/), [Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab](https://onco.cc/trials/nct05215340/), [Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ](https://onco.cc/trials/nct06726265/), [Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen](https://onco.cc/trials/nct04198766/), [Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer](https://onco.cc/trials/nct05620134/), [Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer](https://onco.cc/trials/nct06942234/), [Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)](https://onco.cc/trials/nct04956640/), [Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05533697/), [Study of NEO-201 in Solid Tumors Expansion Cohorts](https://onco.cc/trials/nct03476681/), [Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06890598/), [Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)](https://onco.cc/trials/nct06797635/), [Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)](https://onco.cc/trials/nct02861573/), [Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)](https://onco.cc/trials/nct04634877/), [Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)](https://onco.cc/trials/nct05609968/), [Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)](https://onco.cc/trials/nct04895358/), [Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan](https://onco.cc/trials/nct04956692/), [Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)](https://onco.cc/trials/nct05239741/), [Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)](https://onco.cc/trials/nct05173987/), [Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)](https://onco.cc/trials/nct02362594/), [Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)](https://onco.cc/trials/nct03725059/), [Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu](https://onco.cc/trials/nct07777822/), [Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)](https://onco.cc/trials/nct04380636/), [Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies](https://onco.cc/trials/nct07644039/), [Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC](https://onco.cc/trials/nct06162221/), [Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05186974/), [Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread](https://onco.cc/trials/nct03547973/), [Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer](https://onco.cc/trials/nct06731478/), [Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients](https://onco.cc/trials/nct06284590/), [Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors](https://onco.cc/trials/nct05887492/), [Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer](https://onco.cc/trials/nct06899126/), [Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05784688/), [Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations](https://onco.cc/trials/nct06772623/), [Study to Evaluate D-1553 in Subjects With Solid Tumors](https://onco.cc/trials/nct04585035/), [Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.](https://onco.cc/trials/nct05727904/), [Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05725200/), [Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)](https://onco.cc/trials/nct04626479/), [Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)](https://onco.cc/trials/nct04626518/), [Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)](https://onco.cc/trials/nct06469944/), [Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)](https://onco.cc/trials/nct06780111/), [SWOG S1418 / NRG BR006](https://onco.cc/trials/swog-s1418/), [SWOG S1801](https://onco.cc/trials/swog-s1801/), [SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05570825/), [Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC](https://onco.cc/trials/nct07786428/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/), [TATE and Pembrolizumab (MK3475) in mCRC and NSCLC](https://onco.cc/trials/nct04701476/), [Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)](https://onco.cc/trials/nct05549297/), [Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated](https://onco.cc/trials/nct06908993/), [Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch](https://onco.cc/trials/nct04267848/), [Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer](https://onco.cc/trials/nct03793179/), [Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05096663/), [The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma](https://onco.cc/trials/nct07565285/), [The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)](https://onco.cc/trials/nct04585750/), [This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu](https://onco.cc/trials/nct06758401/), [TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer](https://onco.cc/trials/nct06532812/), [Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06951399/), [TRAP-BTC](https://onco.cc/trials/trap-btc/), [Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC](https://onco.cc/trials/nct04875585/), [Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab](https://onco.cc/trials/nct06371807/), [Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC](https://onco.cc/trials/nct07098988/), [Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors](https://onco.cc/trials/nct05187338/), [TROPION-Breast03](https://onco.cc/trials/tropion-breast03/), [TROPION-Breast05](https://onco.cc/trials/tropion-breast05/), [Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC](https://onco.cc/trials/nct04524689/), [VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma](https://onco.cc/trials/nct03556228/), [VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]](https://onco.cc/trials/nct06264180/), [X4P-001 and Pembrolizumab in Patients With Advanced Melanoma](https://onco.cc/trials/nct02823405/), [Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease](https://onco.cc/trials/nct07750158/)
- people: [Alexander Eggermont](https://onco.cc/people/alexander-eggermont/), [Andrea Necchi](https://onco.cc/people/andrea-necchi/), [Antoni Ribas](https://onco.cc/people/antoni-ribas/), [Arjun V. Balar](https://onco.cc/people/arjun-balar/), [Aurélien Marabelle](https://onco.cc/people/aurelien-marabelle/), [Barbara Burtness](https://onco.cc/people/barbara-burtness/), [Bradley J. Monk](https://onco.cc/people/bradley-monk/), [Brian I. Rini](https://onco.cc/people/brian-rini/), [Caroline Robert](https://onco.cc/people/caroline-robert/), [Domenica Lorusso](https://onco.cc/people/domenica-lorusso/), [Dung T. Le](https://onco.cc/people/dung-le/), [Eric P. Winer](https://onco.cc/people/eric-winer/), [Ezra E. W. Cohen](https://onco.cc/people/ezra-cohen/), [Heather A. Wakelee](https://onco.cc/people/heather-wakelee/), [Jacob Schachter](https://onco.cc/people/jacob-schachter/), [Jae Lyun Lee](https://onco.cc/people/lee-jae-lyun/), [Jason J. Luke](https://onco.cc/people/jason-luke/), [Jeffrey S. Weber](https://onco.cc/people/jeffrey-weber/), [Joaquim Bellmunt](https://onco.cc/people/joaquim-bellmunt/), [Julie R. Brahmer](https://onco.cc/people/julie-brahmer/), [Ken Kato](https://onco.cc/people/ken-kato/), [Lajos Pusztai](https://onco.cc/people/lajos-pusztai/), [Luis A. Diaz Jr.](https://onco.cc/people/luis-diaz/), [Martin Reck](https://onco.cc/people/martin-reck/), [Nicoletta Colombo](https://onco.cc/people/nicoletta-colombo/), [Peter Schmid](https://onco.cc/people/peter-schmid/), [Priyanka Sharma](https://onco.cc/people/priyanka-sharma/), [Qing Zhou](https://onco.cc/people/qing-zhou/), [Ramez N. Eskander](https://onco.cc/people/ramez-eskander/), [Ravindra Uppaluri](https://onco.cc/people/ravindra-uppaluri/), [Robert J. Motzer](https://onco.cc/people/robert-motzer/), [Roy S. Herbst](https://onco.cc/people/roy-herbst/), [Sapna P. Patel](https://onco.cc/people/sapna-patel/), [Shilpa Gupta](https://onco.cc/people/shilpa-gupta/), [Sun Young Rha](https://onco.cc/people/rha-sun-young/), [Tasuku Honjo](https://onco.cc/people/tasuku-honjo/), [Thierry André](https://onco.cc/people/thierry-andre/), [Thomas Powles](https://onco.cc/people/thomas-powles/), [Timothy F. Cloughesy](https://onco.cc/people/timothy-cloughesy/), [Toni K. Choueiri](https://onco.cc/people/toni-choueiri/), [Yelena Y. Janjigian](https://onco.cc/people/yelena-janjigian/)
- key papers: [ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors](https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/), [Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042](https://onco.cc/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/), [Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic non-small-cell lung cancer](https://onco.cc/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/), [Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC](https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/), [Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency](https://onco.cc/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/), [CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer](https://onco.cc/key-papers/paper-clear-nejm-2021/), [Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms](https://onco.cc/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/), [EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer](https://onco.cc/key-papers/paper-ev-302-nejm-2024/), [FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease](https://onco.cc/key-papers/paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021/), [HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/), [Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations](https://onco.cc/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/), [Identification of Lynch syndrome among patients with colorectal cancer](https://onco.cc/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/), [Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack](https://onco.cc/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/), [KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off](https://onco.cc/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/), [KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma](https://onco.cc/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/), [KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-keynote-010-lancet-2016/), [KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer](https://onco.cc/key-papers/paper-keynote-024-nejm-2016/), [KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer](https://onco.cc/key-papers/paper-keynote-048-lancet-2019/), [KEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma](https://onco.cc/key-papers/paper-keynote-054-eggermont-nejm-2018/), [KEYNOTE-057: pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ](https://onco.cc/key-papers/paper-keynote-057-lancet-oncol-2021/), [KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer](https://onco.cc/key-papers/paper-keynote-062-shitara-jama-oncol-2020/), [KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer](https://onco.cc/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/), [KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma](https://onco.cc/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/), [KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer](https://onco.cc/key-papers/paper-keynote-177-nejm-2020/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/), [KEYNOTE-204: pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma](https://onco.cc/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/), [KEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-355-nejm-2022/), [KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma](https://onco.cc/key-papers/paper-keynote-426-nejm-2019/), [KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma](https://onco.cc/key-papers/paper-keynote-483-lancet-2023/), [KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-522-nejm-2022/), [KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery](https://onco.cc/key-papers/paper-keynote-564-nejm-2021/), [KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer](https://onco.cc/key-papers/paper-keynote-590-lancet-2021/), [KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma](https://onco.cc/key-papers/paper-keynote-629-pembrolizumab-cscc-grob-jco-2020/), [KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer](https://onco.cc/key-papers/paper-keynote-689-nejm-2025/), [KEYNOTE-716: adjuvant pembrolizumab versus placebo in completely resected stage IIB or IIC melanoma](https://onco.cc/key-papers/paper-keynote-716-lancet-2022/), [KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer](https://onco.cc/key-papers/paper-keynote-775-nejm-2022/), [KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma](https://onco.cc/key-papers/paper-keynote-811-janjigian-lancet-2023/), [KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer](https://onco.cc/key-papers/paper-keynote-826-nejm-2021/), [KEYNOTE-859: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer](https://onco.cc/key-papers/paper-keynote-859-lancet-oncol-2023/), [KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery](https://onco.cc/key-papers/paper-keynote-942-lancet-2024/), [KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer](https://onco.cc/key-papers/paper-keynote-966-lancet-2023/), [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)](https://onco.cc/key-papers/paper-keynote-a18-os-lancet-2024/), [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)](https://onco.cc/key-papers/paper-keynote-a18-pfs-lancet-2024/), [Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ](https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/), [Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval](https://onco.cc/key-papers/paper-le-mmr-deficiency-science-2017/), [LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma](https://onco.cc/key-papers/paper-leap-012-lancet-2025/), [LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer](https://onco.cc/key-papers/paper-libretto-431-nejm-2023/), [Metastatic Pancreatic Cancer: ASCO Guideline Update](https://onco.cc/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/), [NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer](https://onco.cc/key-papers/paper-nrg-gy018-nejm-2023/), [Pembrolizumab in patients with thymic carcinoma: a single-arm phase 2 study](https://onco.cc/key-papers/paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018/), [Prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade](https://onco.cc/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/), [Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer](https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/), [Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer](https://onco.cc/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/), [SARC028: pembrolizumab in advanced soft tissue and bone sarcoma](https://onco.cc/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/), [Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer](https://onco.cc/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/), [Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge](https://onco.cc/key-papers/paper-tumeh-pd1-adaptive-immune-resistance-nature-2014/), [Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update](https://onco.cc/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/), [ZEBRA: pembrolizumab in advanced small bowel adenocarcinoma](https://onco.cc/key-papers/paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021/)
- drugs: [Anetumab ravtansine](https://onco.cc/drugs/anetumab-ravtansine/), [Epacadostat](https://onco.cc/drugs/epacadostat/), [Ficerafusp alfa](https://onco.cc/drugs/ficerafusp-alfa/), [HB-200](https://onco.cc/drugs/hb-200/), [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Ivermectin](https://onco.cc/drugs/ivermectin/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [PD-L1 IHC 22C3 pharmDx](https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/), [Peginterferon alfa-2b](https://onco.cc/drugs/peginterferon-alfa-2b/), [Petosemtamab](https://onco.cc/drugs/petosemtamab/), [VENTANA MMR RxDx Panel](https://onco.cc/drugs/ventana-mmr-rxdx/)
- terms: [Antibody](https://onco.cc/terms/antibody/), [Colorectal cancer drugs in England: what NICE has recommended](https://onco.cc/terms/colorectal-uk-drug-access/), [Combined positive score (CPS)](https://onco.cc/terms/cps/), [Driver and passenger mutations: the refined somatic mutation theory](https://onco.cc/terms/driver-passenger-model/), [Immune checkpoint](https://onco.cc/terms/immune-checkpoint/), [Immune surveillance and cancer immunoediting](https://onco.cc/terms/immune-surveillance-immunoediting/), [Immune-related endocrinopathies (thyroiditis, hypophysitis)](https://onco.cc/terms/immune-endocrinopathy/), [Immuno-oncology (IO) and checkpoint blockade](https://onco.cc/terms/immuno-oncology/), [Interferon-gamma gene signature (T-cell-inflamed signature)](https://onco.cc/terms/interferon-gamma-signature/), [Lung cancer drugs in England: what NICE has recommended](https://onco.cc/terms/lung-uk-drug-access/), [Merkel cell polyomavirus (MCPyV) status](https://onco.cc/terms/mcpyv-status/), [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/), [MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)](https://onco.cc/terms/mlh1-promoter-methylation/), [Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)](https://onco.cc/terms/pancreatic-cancer-uk-drug-access/), [PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)](https://onco.cc/terms/pd-l1-assay-discordance/), [PD-L1 combined positive score 10 in triple-negative breast cancer](https://onco.cc/terms/pd-l1-cps-10-tnbc/), [POLE ultramutation (POLEmut)](https://onco.cc/terms/pole-ultramutation/), [Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point](https://onco.cc/terms/tnbc-residual-disease-decision/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/), [Tumour proportion score (TPS)](https://onco.cc/terms/tps/), [Tumour-agnostic (tissue-agnostic) approval](https://onco.cc/terms/tumour-agnostic/), [What the NHS in England funds for lymphoma, appraisal by appraisal](https://onco.cc/terms/lymphoma-tx-uk-access/), [WHO Essential Medicines List for cancer](https://onco.cc/terms/who-essential-medicines/)
- pairings: [ADC + checkpoint inhibitor](https://onco.cc/pairings/adc-plus-io/), [Caution: DXd ADC + agents with pneumonitis risk](https://onco.cc/pairings/ild-overlap-caution/), [Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer](https://onco.cc/pairings/chemo-io-first-line-endometrial/), [EGFR-directed bispecific + PD-1 blockade](https://onco.cc/pairings/egfr-bispecific-plus-pd1-hnscc/), [Enfortumab vedotin + pembrolizumab across the bladder cancer continuum](https://onco.cc/pairings/ev-pembro-continuum/), [HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd](https://onco.cc/pairings/her2-gastric-sequence/), [Histology → first-line choice in mesothelioma](https://onco.cc/pairings/histology-directs-first-line-meso/), [IMDC risk → first-line regimen choice (RCC)](https://onco.cc/pairings/risk-directed-first-line-rcc/), [Immunotherapy before surgery rather than with chemoradiation (HNSCC)](https://onco.cc/pairings/io-before-surgery-hnscc/), [Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)](https://onco.cc/pairings/lenvatinib-plus-pembrolizumab/), [Neoadjuvant immunotherapy → response-adapted adjuvant](https://onco.cc/pairings/neoadjuvant-io-response-adapted/), [PD-1 blockade + chemoradiation (locally advanced cervical cancer)](https://onco.cc/pairings/io-plus-crt-cervical/), [PD-1 blockade + chemotherapy in PD-L1-low NSCLC](https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/), [PD-1 blockade + VEGF inhibition](https://onco.cc/pairings/io-plus-vegf/), [PD-1 failure → TIL therapy](https://onco.cc/pairings/io-then-til/), [Personalised neoantigen vaccine + PD-1 blockade](https://onco.cc/pairings/vaccine-plus-pd1/), [Radiotherapy + immunotherapy](https://onco.cc/pairings/radiation-plus-io/), [Sequence: targeted therapy before immunotherapy in driver-positive NSCLC](https://onco.cc/pairings/targeted-before-io-nsclc/)
- ideas: [A funded programme of organ-preservation trials to avoid radical surgery](https://onco.cc/ideas/idea-fund-organ-preservation-programme/), [A neutral platform trial for radiotherapy plus immunotherapy combinations](https://onco.cc/ideas/idea-fund-rt-io-platform/), [A public fund for trials that test less treatment](https://onco.cc/ideas/idea-tr1-public-de-escalation-trial-fund/), [A single calibrated tumour mutational burden across all sequencing panels](https://onco.cc/ideas/idea-tr2-tmb-calibration-standard/), [ADC for residual disease after KEYNOTE-522](https://onco.cc/ideas/idea-post-neoadjuvant-adc/), [An abbreviated approval path for follow-on antibodies within a validated class](https://onco.cc/ideas/idea-fund-abbreviated-pathway-me-too-biologics/), [An advance market commitment for PD-1 biosimilars for lower-income countries](https://onco.cc/ideas/idea-reg-pd1-biosimilar-advance-commitment/), [Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials](https://onco.cc/ideas/idea-reg-biosimilar-no-efficacy-trial/), [Automatic price cuts when a cancer drug's approved indications and volumes expand](https://onco.cc/ideas/idea-reg-market-expansion-repricing/), [Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)](https://onco.cc/ideas/idea-adjuvant-selection-rcc/), [Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response](https://onco.cc/ideas/idea-bladder-preservation-mibc/), [BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer](https://onco.cc/ideas/idea-atc-triplet-io/), [Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial](https://onco.cc/ideas/idea-nl-diet-covariates-io-trials/), [ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative](https://onco.cc/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/), [Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable](https://onco.cc/ideas/idea-tr1-extended-interval-checkpoint-dosing/), [Extra exclusivity for sponsors who run treatment-duration and de-escalation trials](https://onco.cc/ideas/idea-fund-duration-trial-exclusivity/), [Fund trials that test shorter courses of the most expensive adjuvant drugs](https://onco.cc/ideas/idea-cost-shorter-course-trials/), [Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease](https://onco.cc/ideas/idea-tnbc-de-escalation-for-exceptional-responders/), [Give subcutaneous immunotherapy in community clinics and at home](https://onco.cc/ideas/idea-cost-subcutaneous-community/), [Harmonise PD-L1 testing for triple-negative breast cancer around one scored assay, with external quality assurance](https://onco.cc/ideas/idea-tnbc-pd-l1-assay-harmonisation/), [Home infusion and local blood draws for trial drugs after the first cycles](https://onco.cc/ideas/idea-tr1-home-infusion-trial-drugs/), [HPV circulating tumour DNA to guide cervical cancer therapy](https://onco.cc/ideas/idea-hpv-ctdna-cervical/), [Make six-weekly immunotherapy the default schedule](https://onco.cc/ideas/idea-cost-extended-interval-default/), [Measure the late effects of the treatments being given now, not the ones given in 1975](https://onco.cc/ideas/lymphoma-ev-late-effects-of-the-treatments-given-now/), [Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC](https://onco.cc/ideas/idea-neoadjuvant-adc-io/), [Neoadjuvant immunotherapy with surgical window for glioblastoma](https://onco.cc/ideas/idea-neoadjuvant-io-glioblastoma/), [One digital PD-L1 scale that maps across all the competing assays](https://onco.cc/ideas/idea-tr2-pdl1-digital-calibration/), [Pay a different price for the same cancer drug depending on the indication](https://onco.cc/ideas/idea-reg-indication-specific-pricing/), [Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments](https://onco.cc/ideas/idea-fund-payer-funded-pragmatic-trials/), [Photoimmunotherapy as an in situ vaccine with PD-1 blockade](https://onco.cc/ideas/idea-photoimmunotherapy-plus-pd1/), [Pooled procurement and voluntary licensing for essential cancer medicines in low-income countries](https://onco.cc/ideas/idea-moon-pooled-procurement-licensing-pool/), [Predict immune side-effects before they happen and pre-empt them](https://onco.cc/ideas/idea-moon-irae-prediction-and-prevention/), [Price a cancer drug by how well it works in each cancer](https://onco.cc/ideas/idea-cost-indication-based-pricing/), [Publicly funded dose-reduction trials of expensive approved drugs](https://onco.cc/ideas/idea-tr1-public-dose-reduction-trials-of-approved-drugs/), [Publicly funded trials of lower and less frequent doses of expensive cancer drugs](https://onco.cc/ideas/idea-reg-public-deescalation-trials-for-cost/), [Randomise a cheap antihistamine alongside immunotherapy](https://onco.cc/ideas/idea-reg-antihistamine-plus-io-trial/), [Randomised trials of stopping immunotherapy after one year versus continuing](https://onco.cc/ideas/idea-tr1-immunotherapy-stop-trials/), [Require head-to-head trials against the best in class for later entrants](https://onco.cc/ideas/idea-fund-head-to-head-mandate/), [Restore weight-based dosing and vial sharing for immunotherapy in the label](https://onco.cc/ideas/idea-reg-weight-based-io-dosing-label/), [Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed](https://onco.cc/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/), [Shorter exclusivity for later-in-class drugs without added benefit](https://onco.cc/ideas/idea-fund-benefit-indexed-exclusivity/), [Subscription pricing for checkpoint inhibitors: fixed national fee, unlimited use](https://onco.cc/ideas/idea-reg-io-subscription-national/), [Take faecal transplant plus immunotherapy to a definitive trial](https://onco.cc/ideas/idea-bio2-fmt-plus-checkpoint-phase3/), [Test flat versus weight-based dosing of antibodies, and use dose banding to cut waste](https://onco.cc/ideas/idea-tr1-weight-based-vs-flat-dosing-trials/), [Test one-tenth-dose immunotherapy where the full dose is unaffordable](https://onco.cc/ideas/idea-cost-low-dose-immunotherapy-trials/), [Watch routine care for drug combinations that quietly make cancer treatment worse](https://onco.cc/ideas/idea-tr2-antagonism-surveillance/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/), [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/), [Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity](https://onco.cc/roadmaps/immunotherapy-roadmap/), [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- institutions: [Institut Jules Bordet](https://onco.cc/institutions/institut-jules-bordet/), [Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center](https://onco.cc/institutions/johns-hopkins/), [Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne](https://onco.cc/institutions/chuv-lausanne/)
- pathways: [Bladder cancer (KEGG map)](https://onco.cc/pathways/bladder-cancer-signalling/), [Breast cancer (KEGG map)](https://onco.cc/pathways/breast-cancer-signalling/), [Colorectal cancer (KEGG map)](https://onco.cc/pathways/colorectal-cancer-signalling/), [Endometrial cancer (KEGG map)](https://onco.cc/pathways/endometrial-cancer-signalling/), [Gastric cancer (KEGG map)](https://onco.cc/pathways/gastric-cancer-signalling/), [Melanoma (KEGG map)](https://onco.cc/pathways/melanoma-signalling/), [Mismatch repair & microsatellite instability](https://onco.cc/pathways/mismatch-repair-msi/), [Mutagenesis & mutational signatures](https://onco.cc/pathways/mutagenesis-signatures/), [Non-small cell lung cancer (KEGG map)](https://onco.cc/pathways/nsclc-signalling/), [Nutrient competition & metabolic immunosuppression](https://onco.cc/pathways/nutrient-competition-tme/), [Oncogenic viruses](https://onco.cc/pathways/oncogenic-viruses/), [Pancreatic cancer (KEGG map)](https://onco.cc/pathways/pancreatic-cancer-signalling/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [Renal cell carcinoma (KEGG map)](https://onco.cc/pathways/renal-cell-carcinoma-signalling/), [T-cell exhaustion](https://onco.cc/pathways/t-cell-exhaustion/), [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)

---
JSON: https://onco.cc/api/v1/entities/pembrolizumab.json